Aducanumab And The US Pricing Debate: A New Hook, But Still A Fuzzy Picture

Some Democratic senators are not fans of FDA’s approval of Biogen/Eisai’s Aduhelm, and are even more critical of the price of the Alzheimer’s therapy. That is providing a new hook to urge action on creating a federal price ‘negotiation’ program – but not any more clarity on a viable path to enacting one.

United States Capitol Building in Washington DC USA
• Source: Shutterstock

The $56,000 list price for Biogen, Inc./Eisai Co., Ltd.’s newly approved Alzheimer’s therapy Aduhelm (aducanumab-avwa) is providing a new hook to energize Congressional efforts to address drug pricing – but does not appear to be triggering any fundamental shift in the dynamics of the drug pricing debate early in the Biden Administration.

Finance Committee Chair Ron Wyden kicked off a 10 June HHS budget hearing by decrying the “unconscionable” price of Aduhelm....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access